Stoke Therapeutics ((STOK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stoke Therapeutics is conducting a Phase 3 study titled ‘EMPEROR’ to evaluate the efficacy, safety, and tolerability of zorevunersen (STK-001) in patients with Dravet Syndrome. The study aims to assess whether zorevunersen can reduce major motor seizure frequency and improve behavior, cognition, and quality of life for patients.
Zorevunersen is an antisense oligonucleotide designed to increase the expression of the Nav1.1 protein by modulating RNA, not altering DNA. This treatment aims to restore physiological levels of Nav1.1, which are typically reduced in Dravet Syndrome patients.
The study is a global, multicenter, randomized, double-blind, sham-controlled trial with a parallel group design. Participants are randomly assigned to receive either zorevunersen or a sham comparator, with masking applied to participants, care providers, investigators, and outcomes assessors.
The study began in June 2025, with primary completion estimated for a future date. The last update was submitted on June 24, 2025, indicating ongoing recruitment.
This study could significantly impact Stoke Therapeutics’ stock performance if successful, given the unmet need in Dravet Syndrome treatment. Investors should watch for updates, as positive results could enhance investor sentiment and position Stoke favorably against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.